Home > Products > Antibodies > Flow Cytometry (FACS) Antibodies

Anti-Human CD274/PD-L1/B7-H1 Antibody (SAA0088) (HV974107)

Datasheet Share product Copy info

Anti-Human CD274/PD-L1/B7-H1 Antibody (SAA0088)

Anti-Human CD274/PD-L1/B7-H1 Antibody (SAA0088)

Price(USD): $

Spec:

50ug
100ug

Number:

Contact us

Overview
Images
References
Datasheet

Overview

Catalog No.	HV974107
Description	Anti-Human CD274/PD-L1/B7-H1 Antibody (SAA0088) [SAA0088] (HV974107) is a human monoclonal antibody detecting B7-H1 in FCM. Suitable for Human. Highlights ●Flow Cytometry — Validated for flow cytometry applications.
Species reactivity	Human
Applications	FCM
Host species	Human
Isotype	IgG4, kappa
Clone ID	SAA0088
Clonality	Monoclonal
Target	B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274
Endotoxin level	Please contact with the lab for this information.
Purity	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	Q9NZQ7
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Background	Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi). 1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443 2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410 3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417 4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419 5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298 6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077 7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201
Note	For research use only.

Images

SDS-PAGE

SDS-PAGE for Anti-Human CD274/PD-L1/B7-H1 Antibody (SAA0088)

References

Datasheet

Anti-Human CD274/PD-L1/B7-H1 Antibody (SAA0088).pdf

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

=

Concentration

×

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

×

V₁ (Stock Vol.)

=

Working Solution

C₂ (Working Conc.)

×

V₂ (Working Vol.)

Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: support@abinScience.com

Distributor list

Anti-Human CD274/PD-L1/B7-H1 Antibody (SAA0088)